Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...
Business Insider8d
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...
Finanznachrichten7d
Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
Zacks.com on MSN18h
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago. These ...
Zacks.com on MSN5d
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...
Chardan Capital downgrades CARGO Therapeutics, Inc. (CRGX) to a Hold
CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...
Investing6d
Crispr Therapeutics AG (CRSP)
CRISPR/Cas9 gene editing outfits Editas Medicine (EDIT -2.2%), Intellia Therapeutics (NTLA -2%) and CRISPR Therapeutics (CRSP -3.6%) are all under pressure mid-session.The... Recent SEC filings ...